Skip to main content

Table 4 Kaplan-Meier estimated sustained ulcer-free rates (95% confidence interval) at 52 weeks, presented by patient subgroup (full analysis set)

From: Safety and efficacy of long-term esomeprazole 20 mg in Japanese patients with a history of peptic ulcer receiving daily non-steroidal anti-inflammatory drugs

Subgroup Esomeprazole 20 mg once daily (n=130)
Sex  
  Men (n=35) 97.0% (91.1, 100)
  Women (n=95) 95.5% (91.1, 99.8)
Age  
  ≤64 years (n=63) 96.7% (92.2, 100)
  ≥65 to ≤74 years (n=43) 92.3% (83.9, 100)
  ≥75 years (n=24) 100% (100, 100)
Helicobacter pylori infection  
  Positive (n=57) 98.1% (94.3, 100)
  Negative (n=73) 94.3% (88.8, 99.7)
Use of corticosteroids  
  Yes (n=32) 96.7 (90.2, 100)
  No (n=98) 95.6 (91.4, 99.8)
Type of NSAID at baseline  
  COX-2-selective (n=21)a 94.7% (84.7, 100)
  Non-selective (n=109) 96.1% (92.3, 99.8)
CYP2C19 genotype  
  Poor metaboliser (n=22) 95.5% (86.8, 100)
  Hetero extensive metaboliser (n=68) 93.8% (87.9, 99.7)
  Homo extensive metaboliser (n=40) 100% (100, 100)
  1. aIncluding celecoxib, etodolac and nabumetone.
  2. Abbreviations: COX, cyclo-oxygenase; CYP2C19, cytochrome P450 2C19; NSAID, non-steroidal anti-inflammatory drug.